title: [An analysis of double autologous hemopoietic stem cell transplantation for hematological malignancies].
abstract: OBJECTIVE
  To analyse the clinical efficacy of the double autologous hemopoietic stem cell transplantation (DAHSCT) for hematological malignancies.
  
  
  METHODS
  19 hematological malignant disease patients received the first AHSCT within 12 months after diagnosis. The first conditioning regimen was VP-16 or Ara-C, CTX +, TBI, nine of them received BCNU additionally. All patients received the second AHSCT in 4 to 10 months after the first AHSCT. The second conditioning regimen was VP-16 (or Ara-C), CTX +, Mel.
  
  
  RESULTS
  All patients had rapidly hemopoietic reconstitution, the first hemopoietic reconstitution is faster than the second. There was no AHSCT related death. The median follow up duration was 1078 days. 12 of the 19 patients were still alive during the analysis. The 3-year disease-free suvival (DFS) was 63% +/- 10%. Those patients who had more blasts in bone marrow at the second AHSCT than the first AHSCT had greater probability to relapse.
  
  
  CONCLUSIONS
  DAHSCT can be safety performed as an important treatment method in hematological malignancies.
authors.affiliation: Department of Hematology the PLA General Hospital of People's Liberation Army of China, Beijing 100853, China.
authors.forename: Bolong
authors.initials: B
authors.lastname: Zhang
authors.forename: Wenrong
authors.initials: W
authors.lastname: Huang
authors.forename: Wanming
authors.initials: W
authors.lastname: Da
authors.forename: Zhanqiang
authors.initials: Z
authors.lastname: Zhang
authors.forename: Shanqian
authors.initials: S
authors.lastname: Yao
authors.forename: Chunji
authors.initials: C
authors.lastname: Gao
authors.forename: Xiaoping
authors.initials: X
authors.lastname: Han
authors.forename: Xiaoxiong
authors.initials: X
authors.lastname: Wu
authors.forename: Quanshun
authors.initials: Q
authors.lastname: Wang
authors.forename: Li
authors.initials: L
authors.lastname: Yu
authors.forename: Miao
authors.initials: M
authors.lastname: Zhang
authors.forename: Haijie
authors.initials: H
authors.lastname: Jin
mesh_terms: D000293:Adolescent; D000328:Adult; D005260:Female; D019337:Hematologic Neoplasms / Q000401:mortality / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008223:Lymphoma / Q000401:mortality / Q000628:therapy; D008228:Lymphoma, Non-Hodgkin / Q000401:mortality / Q000628:therapy; D008297:Male; D009190:Myelodysplastic Syndromes / Q000401:mortality / Q000628:therapy; D014182:Transplantation, Autologous; D016896:Treatment Outcome